IDH1 and central nervous system cancer: The detection of IDH1/2 mutations through the measurement of the 2-hydroxyglutarate (2-HG) oncometabolite levels by MRSI, despite a possible spectral overlap with other metabolites, would be remarkable only if referred to the whole glioma group [37].